(Q39372736)

11 September 2017

title

Old and new challenges in Chagas disease (English)

1 reference

José Antonio Pérez-Molina

11 September 2017

0 references

object named as

Jose A Pérez-Molina

1

0 references

author name string

Angela Martinez Perez

2

1 reference

11 September 2017

Francesca F Norman

3

1 reference

11 September 2017

Begoña Monge-Maillo

4

1 reference

11 September 2017

Rogelio López-Vélez

5

1 reference

11 September 2017

publication date

28 July 2015

1 reference

Lancet Infectious Diseases

11 September 2017

published in

1 reference

11 September 2017

volume

15

1 reference

11 September 2017

issue

11

1 reference

11 September 2017

page(s)

1347-1356

1 reference

Kissing bugs. The vectors of Chagas.

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

1 reference

7 January 2021

Frequency of the congenital transmission of Trypanosoma cruzi: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Chagas disease: changes in knowledge and management

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Chagas disease: a Latin American health problem becoming a world health problem

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

An approach to the management of Trypanosoma cruzi infection (Chagas' disease) in immunocompromised patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Management of Trypanosoma cruzi coinfection in HIV-positive individuals outside endemic areas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Chagas disease in the immunosuppressed host

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Oral transmission of Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Intensified surveillance and insecticide-based control of the Chagas disease vector Triatoma infestans in the Argentinean Chaco

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

An Estimate of the Burden of Chagas Disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Chagas disease in Spain: need for further public health measures

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Transmission of Tropical and Geographically Restricted Infections during Solid-Organ Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Chagas disease and the US blood supply

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Acute Chagas' disease in a recipient of a bone marrow transplant in Spain: case report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

The epidemiological relevance of family study in Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Treatment of congenital Chagas' disease diagnosed and followed up by the polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

ELISA versus PCR for diagnosis of chronic Chagas disease: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

A systematic review of high quality diagnostic tests for Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Identification of a Western blot pattern for the specific diagnosis of Trypanosoma cruzi infection in human sera.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Validation of a rapid immunochromatographic assay for diagnosis of Trypanosoma cruzi infection among Latin-American Migrants in Geneva, Switzerland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Dried blood as an alternative to plasma or serum for Trypanosoma cruzi IgG detection in screening programs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Towards the establishment of a consensus real-time qPCR to monitor Trypanosoma cruzi parasitemia in patients with chronic Chagas disease cardiomyopathy: a substudy from the BENEFIT trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

1 reference

7 January 2021

Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Gastro-intestinal Chagas disease in migrants to Spain: prevalence and methods for early diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

II Guidelines for perioperative evaluation of the Brazilian Society of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Chronic phase of Chagas disease: why should it be treated? A comprehensive review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Chagas disease in Latin American migrants: a Spanish challenge.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Safety of benznidazole use in the treatment of chronic Chagas' disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Tolerance and safety of nifurtimox in patients with chronic chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Tolerance of benznidazole in treatment of Chagas' disease in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Treatment of chronic Chagas' disease with an association of nifurtimox and corticoid

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

The use of steroids to prevent cutaneous reactions to benznidazole in patients with Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Criteria of Chagas disease cure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Stroke in asymptomatic Trypanosoma cruzi-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Predictors of mortality in chronic Chagas disease: a systematic review of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Chagas disease and mortality in old age as an emerging issue: 10 year follow-up of the Bambuí population-based cohort study (Brazil)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Infections in solid organ transplantation in special situations: HIV-infection and immigration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Accurate real-time PCR strategy for monitoring bloodstream parasitic loads in chagas disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Heart transplantation in 107 cases of Chagas' disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Chagas' disease in patients with kidney transplants: 7 years of experience 1989-1996

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Chagas disease in bone marrow transplantation: an approach to preemptive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Reactivation of Chagas disease in a bone marrow transplant patient: case report and review of screening and management

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Reactivation of Chagas' disease during therapy of acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Reactivation of Chagas' disease in a patient with non-Hodgkin's lymphoma: gastric, oesophageal and laryngeal involvement

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Immunosuppression and Chagas disease: a management challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Reactivation of Chagas disease by immunosuppressive therapy in a patient with systemic lupus erythematosus: report of an exceptional case

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Clinical follow-up of responses to treatment with benznidazol in Amazon: a cohort study of acute Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Treatment of Trypanosoma cruzi-infected children with nifurtimox: a 3 year follow-up by PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Usefulness of PCR-based assays to assess drug efficacy in Chagas disease chemotherapy: value and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Microsatellite and mini-exon analysis of Mexican human DTU I Trypanosoma cruzi strains and their susceptibility to nifurtimox and benznidazole.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Lack of correlation between in vitro susceptibility to Benznidazole and phylogenetic diversity of Trypanosoma cruzi, the agent of Chagas disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900243-1

7 January 2021

10.1016/S1473-3099(15)00243-1

Identifiers

DOI

1 reference

11 September 2017

1 reference